Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Stymied By Reauthorization Terms That May Slow Ingredient Development

This article was originally published in The Tan Sheet

Executive Summary

FDA is stumped on interpreting and enforcing a provision in the FDA Amendments Act of 2007 that could have a chilling effect on development of new functional food and dietary supplement ingredients, an FDA official and an industry leader say

You may also be interested in...



Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry

FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say

Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry

FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say

Congress Did Not Intend FDAAA Sec. 912 To Apply To Supplements – Industry

FDA should not subject dietary supplements to an FDA Amendment Act of 2007 provision that, if interpreted broadly, would block supplement sales, restrict innovation and discourage pre-market safety and efficacy tests, industry leaders say

Related Content

Topics

UsernamePublicRestriction

Register

PS101432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel